Podcasts about new medicines

In this episode of The Rumors Are True, we're joined by Chad Shellabarger, bassist of the influential post-hardcore band Dead Poetic. From their early days in the underground scene to becoming a staple of the 2000s alternative music movement, Dead Poetic left a lasting mark with their emotionally charged lyrics, heavy-hitting sound, and unforgettable albums like New Medicines and Vices.Chad takes us behind the scenes, sharing stories about the band's formation, life on the road, and the highs and lows of the music industry. We talk about the creative process, the evolution of their sound, and what ultimately led to the band stepping away from the spotlight. Plus, Chad gives us an update on what he's been up to since his days in Dead Poetic and reflects on the band's legacy in today's music landscape.If you grew up listening to Dead Poetic or are just discovering their music, this is an episode you won't want to miss!Produced by Wesley Hill @thebigwesArtwork by Jared Chase Bowser @jaredchasebowserMusic by Brian Jerin R.I.P.

Listen to the top News from Australia and India in Hindi.

Sam is Head of Market Access Canada at Incyte Biosciences Canada and joins the podcast to discuss the evolving market access landscape in Canada. As part of his conversation with Louise, he describes the unique challenges that market access leaders in the country are facing. Useful resources referenced in this podcast: March 2024 - Canadian Health Policy Institute (Patented Medicines Expenditure in Canada 1990 – 2022)https://www.canadianhealthpolicy.com/product/patented-medicines-expenditure-in-canada-1990-2022-8th-edition/January 2024 – Conference Board of Canada (Patented Medicines Expenditure in Canada 1990–2022 8TH Edition)https://www.conferenceboard.ca/wp-content/uploads/2022/10/access-and-time-to-patient_jan2024.pdfInnovative Medicines Canada – Access to Medicinehttps://innovativemedicines.ca/browse-by/access-to-medicine/April 2023 – Canadian Health Policy Journal (New cancer drugs in Canada 2012 to 2021: an economic analysis of cost, benefit, availability, and public insurance coverage)https://www.canadianhealthpolicy.com/wp-content/uploads/2022/01/SKINNER-APR-23-New-cancer-drugs-in-Canada-2012-to-2021-final-1.pdfApril 2022 – Canadian Health Policy Institute (Access to New Medicines in Canada 2016 – 2021)https://www.canadianhealthpolicy.com/posts/access-to-new-medicines-in-canada-2016-2021-federal-provincial-public-drug-programs-and-private-sector-drug-plans/The opinions shared in this podcast are Sam's own views and not representative of the company he is working for. 

New developments in the world of AI could make the discovery of medicines faster and cheaper for consumers. It's been found generative AI can be taught to process and examine new molecules - with the potential to unveil new treatments. Milford Asset Management's Deborah Lambie explains the benefits of these new developments. LISTEN ABOVESee omnystudio.com/listener for privacy information.

Pharmac's getting a funding boost for new cancer drugs in a pre-commitment from next year's Budget. The Government's announced money for up to 26 cancer treatments, in an overall package of up to 54 new medicines. ZB senior political correspondent Barry Soper explains further. LISTEN ABOVESee omnystudio.com/listener for privacy information.

Do we need to evolve the bar on evidence required for drug reimbursement? The gold standard endpoint for assessing the benefit of anti-cancer drugs has been overall survival (OS) however, more recently, there has been a trend toward using surrogate clinical trial endpoints such as progression free survival (PFS) and event-free survival (EFS). As treatments improve and patients are living longer, using OS as a primary endpoint can mean a longer time until a result is obtained. In this podcast, Dr Rebecca Tay, Medical Oncologist at Royal Hobart Hospital and ICON, discusses the critical role of improvement in quality of life in assessing drugs that are funded on the PBS, the nuances around clinical trial endpoints and the need for surrogate endpoints that accurately predict for OS and a reimbursement system that brings beneficial treatments to patients faster. Professor Nick Pavlakis, Chair of TOGA and Medical Oncologist at Royal North Shore Hospital and Genesis Care and Dr Deme Karikios, Immediate Past Chair of MOGA and Medical Oncologist from Nepean Hospital Sydney join the conversation. https://jamanetwork.com/journals/jama/article-abstract/2817337

Album Anniversaries for the week of 4/1 - 4/7. Another CCM heavy week. I talk about one of my favorites, "Zeal" by Kings Kaleidoscope and probably piss some people off with my take on Dead Poetics "New Medicines." Plus a ton of other albums and a preview of next week's posts. Music by: Peg and The Rejected "Sing It Out At Street Level"

We're back with Part 2 of our conversation with Brandon Rike & Zachary Miles from Dead Poetic. This time we're going through New Medicines track-by-track. Be sure to catch Part 1 of our conversation if you haven't already.If you like what you hear, please rate, review, subscribe, and follow!Connect with us here:Email: contact@churchjamsnow.comSite: https://www.churchjamsnow.com/IG: @churchjamsnowTwitter: @churchjamsnowFB: https://www.facebook.com/churchjamsnowpodcastPatreon: https://www.patreon.com/churchjamsnowpodcast

We're celebrating the 20th anniversary of New Medicines, and we're joined by Brandon Rike and Zachary Miles from Dead Poetic. We talked so much we're splitting the episode into two parts. In this episode you'll hear Brandon & Zachary's origin stories, musical influences, and the history of Dead Poetic leading up to the record. Lookout for Part 2 where we go track-by-track through New Medicines.If you like what you hear, please rate, review, subscribe, and follow!Connect with us here:Email: contact@churchjamsnow.comSite: https://www.churchjamsnow.com/IG: @churchjamsnowTwitter: @churchjamsnowFB: https://www.facebook.com/churchjamsnowpodcastPatreon: https://www.patreon.com/churchjamsnowpodcast

In this Tech Barometer podcast segment, Debojyoti “Debo” Dutta, vice president of engineering, AI at Nutanix shares his passion for...[…]

In this Tech Barometer podcast segment, Debojyoti “Debo” Dutta, vice president of engineering, AI at Nutanix shares his passion for...[…]

For more information on the Pediatric Executive Development System, visit us: https://thepediatriclounge.com/pediatric-development The Podcast is a member-supported venture; please help us continue to bring the content to you by supporting the show. Click HERE NOW.End CanWhat does a CEO closing access to care for children make? "Kenneth A Samet (Ceo And President) | $15,771,396"  Dr. Scott Krugman's impact on Pediatrics, his experience as the grandson of a pioneering pediatrician, and his journey in the field. The discussion also covers realities about Medicaid financing of children's healthcare, the adverse effects of closures in pediatric services, and the need to rethink investment in pediatric care. It also discusses the value discrepancy in pediatric inventions such as the Hepatitis B vaccine and underscores the negative impact of bureaucratic procedures in the medical field. Lastly, it highlights the necessity for conversations about financing long-term health investments and re-evaluating health practices.00:00 Introduction to Pediatric Executive Development System (PEDS)00:33 Interview with Dr. Scott Krugman01:20 Dr. Scott Krugman's Background and Career05:41 Dr. Scott Krugman's Family Legacy in Pediatrics15:35 Dr. Scott Krugman's Experience in Costa Rica17:36 Closure of Pediatric Services at Franklin Square Hospital25:14 Impact of Hospital Closures on Pediatric Care29:25 Choosing the Right Hospital for Your Child30:06 The Struggles of Pediatric Healthcare30:35 The Threat of Future Epidemics31:12 Introducing the Pediatric Executive Development System31:46 The Challenges of Pediatric Hospital Capacity32:10 The Impact of Overcrowding on Pediatric Care33:11 The Importance of Pediatric Access33:25 The Future of Pediatric Urgent Care33:46 The Evolution of Pediatric Medicine34:46 The Financial Challenges in Pediatric Medicine35:54 The Need for Investment in Pediatric Care38:05 The Role of Vaccines in Pediatric Care40:13 The Future of Pediatric Medicine Financing41:28 The Impact of New Medicines on Pediatric Care45:24 The Need for a Different Finance Solution for Children51:37 The Challenges of Independent Pediatric Practices54:44 The Role of Telemedicine in Pediatric CareSupport the show

Union and Allison Transmission negotiating again, IMPD released deadly police shooting video, 'Jack's Donuts' matriarch dies, Colts gear up for Saturday, Pacers alley-oop, Trump asks U-S Supreme Court to weigh in ballot battle, Curling slides into downtown Indianapolis, and more...See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week's radio show is the second of a two-part series on new medicines for treating obesity. This episode features Dr. Robert Lustig, neuroendocrinologist and anti-obesity crusader. He discusses the uses and disadvantages of drugs such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro). In addition, he offers a completely different way to combat obesity. You […]

Our guest today is Dr. Ashley Zehnder, co-founder and CEO of Fauna Bio. Fauna is a revolutionary young biotech company using comparative genomics of an array of non-traditional mammalian models to discover new therapeutic opportunities for people. What do ground squirrels have to do with treating battlefield trauma? Only one way to find out … Visit ⁠TPM E33⁠ for highlights and links from this episode.

This week's radio show is the first of a two-part series on new medicines for treating obesity. This episode features obesity expert Dr. Jamy Ard. He'll describe how he uses drugs such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro). What are the pros and cons of these medications, and what other approaches are available? You […]

Peter Kolchinsky, Managing Partner at RA Capital Management, breaks down a new white paper with Entity rRisk that aims to get the math correct when measuring the value of new medicines; a new report says the HHS Office for Civil Rights wants an update to a 50-year-old law to prevent disability-based discrimination; and Patients Rising Now is supporting The Protecting Health Care for All Patients Act. RA Capital Management U.S. Department of Health and Human Services Webpage: HHS Issues New Proposed Rule to Strengthen Prohibitions Against Discrimination on the Basis of a Disability in Health Care and Human Services Programs Congressional Budget Office Webpage: H.R. 485, Protecting Health Care for All Patients Act of 2023  

Cancer doctors have warned they cannot prescribe the drugs they feel are appropriate to one-in-four patients due to shortcomings in the system for approving new medicines. Speaking to Newstalk Breakfast this morning was Micheal McCarthy, consultant medical oncologist and one of the authors of the presentation.

Cancer doctors have warned they cannot prescribe the drugs they feel are appropriate to one-in-four patients due to shortcomings in the system for approving new medicines. Speaking to Newstalk Breakfast this morning was Micheal McCarthy, consultant medical oncologist and one of the authors of the presentation.

I've had a busy few weeks. I'd like to thank that's a good thing, but it could be avoidance. I'm really good at that. --- Send in a voice message: https://podcasters.spotify.com/pod/show/aestheticallydope/message

Today's episode discusses how Traditional Indigenous Healers expect to see new, more potent medicines coming into this world. The more challenging our times get, the more powerful the medicines will need to be in order to bring about balance. The Q'ero expected to see new levels of mastery achieved in their healing tradition. They also expected new souls with unique energetics and gifts to enter our world. These new "medicines" in the form of people will need help being birthed and can sometimes come into this world with a rigid set of challenges meant to help them mature into their calling and purpose. Healers are here to help guide them onto the path of blossoming their powers and abilities, using traditional indigenous medicines and wisdom.  www.traditionalmedicinemiami.comhttps://www.instagram.com/traditionalmedicinemiami

Have you ever wondered where osteoporosis medicines come from? The lads went on a journey to find out by talking to Dr Cesar Libanati and Dr Alistair Henry about discovering new medicines and getting them to you the listener. The interview is a fascinating insight into how to change the world and make it a better place for us all to live.Cesar Libanati is the head of external affairs and medical strategy for bone at UCB. Alistair Henry is the Head of discovery science and UK Site head at UCB.

Daphne Koller was a precociously clever child. She completed her first degree – a double major in mathematics and computer science – when she was just 17 and went on to become a distinguished Professor at Stanford University in California. But before long she'd given up this comfortable academic position to create the biggest online education platform in the world. In 2018, she founded the drug discovery company Insitro hoping to create a space where data scientists and molecular biologists could work together as equals. Daphne tells Jim Al-Khalili how a single question from her supervisor nudged her to use her considerable mathematical ability to do something useful and why she believes the time is right for artificial intelligence to discover new medicines. Producer: Anna Buckley

Two new medicines are set to be funded by Pharmac, potentially affecting tens of thousands of patients. A proposal released this morning would fund Spinraza, a treatment for spinal muscular atrophy, that currently costs up to 390-thousand dollars a year. The second proposal would fund adrenaline auto-injector pens, such as EpiPens, for those with life-threatening allergies. Health Minister Andrew Little spoke to Guyon Espiner.

A new computer model of the stomach and how well pills dissolve in it has been developed by engineers at Johns Hopkins, led by Rajat Mittal. Mittal says work so far with the model, called ‘StomachSim,' has opened his eyes to the central role the organ plays in human health. Rajat Mittal: Engineers like me […]

Catch the Ask AI interview with Amit Deshwar, VP and Head of Predictive Systems at Deep Genomics, the AI Workbench used to prioritize transformational RNA therapeutics for genetic diseases. Get all the links from our episode post

Join Amy Greeson as she recounts her expeditions in search of new medicines in remote Jungles and Rain forests.  Her encounters with gifted native healers, arrest and interrogation in the Congo, disembodied spirits along with poisonous caterpillars, swarming insects and deadly vipers.Amy is a Pharmacist, a Fellow of The Explorers Club and a member of the Society of Woman Geographers. She has led expeditions into the jungles and rain forests of the Amazon, Madagascar, Papua New Guinea and the Republic of the Congo seeking out native healers and the natural medicines they use. Amy works to document and preserve these indigenous healing methods in the hope that one day they may be successfully used in Western medicine.  Her life is a true story of adventure in the name of science. Follow Amy Greeson at her Facebook Page.The website for her book https://andthesilentspoke.comHosted by Michael J. ReinhartMichaelJReinhart.com

Today's brilliant guest is Dr. Brian Walker, Western Australia MP and a seriously refreshing source of optimism.  You may know him for his fierce cannabis advocacy in the Western Australia Parliament, or his reasonable and informed stance on utilising MDMA, psilocybin and LSD for the treatment of mental health conditions. You may know him for his nuanced approach to fostering financial, psychophysical and community wellbeing, or you may even know him for his mastery of the Japanese martial art practices of kendo and iaido. Whatever you may know him for, I've come to consider him as the unspoken leader of Australia's rational revolution. Dr. Brian's work: https://lcwaparty.org.au/team-members/brian-walker/ Youtube: https://www.youtube.com/channel/UCCIGBIf3b385BV5d48Y1U2A LinkedIn: https://www.linkedin.com/in/brianwalkermlc/ If you enjoy today's episode, let me know! Drop a review. Send me a letter. 

On this episode, Dr. Louis Meyers talks with Dr. Phillip Schein, A medical oncologist and former vice-president of Smith-Kline. He will talk us through how new medicines are developed and approved by the FDA. He also has helped oversee medical research done on the NASA space station, and will talk about that.

This is a recording of webinar discussion, facilitated by Ben, about the importance of digital infrastructure, the role of collaboration to strengthen these systems and empower digital innovation, and the future of digital health. Brought to you by the Bay Area Global Health Alliance, with Co-creation Hub, Mastercard and Zenysis Technologies, as part of Resonance's Inclusive Innovation Exchange.Introduced by Resonance's Marissa Gilman, Ben is joined by Clay Sader, the Chief Operating Officer and former Director of Product at Zenysis Technologies. As the company's first hire, Clay developed product strategy, shaped embedded delivery models, and launched projects in Ethiopia, Zambia, South Africa, Togo, and Liberia. Today Clay oversees global operations, business development, and product delivery.Temi Filani is a public health professional and currently leads the Design for Health Practice with Co-creation Hub (CcHUB), where she is responsible for strategic planning, thought leadership, partnerships, and business development with the goal of spurring design, innovation, and use of technology in the healthcare space across Africa. She is also currently enrolled in the Master of Healthcare Quality and Safety program at Harvard Medical School.Paul Musser leads Mastercard's Global Pharmaceutical and MedTech vertical. Using innovative business models and Mastercard's extensive technology resources, he and his teams look for ways to further enable the life-improving potential of medicine. Paul has been with MasterCard since 2007, where he has held a variety of roles, including sales, product development, and corporate strategy.This episode was made in partnership with the Bay Area Global Health Alliance, a network of academic institutions, nonprofits, and innovative tech, biotech and pharmaceutical companies -- all committed to advancing global health equity and #innovation.You can find this episode and past episodes of A Shot in the Arm Podcast with Ben Plumley on this (and other) podcast platforms. Please subscribe and give us 5 stars!https://bayareaglobalhealth.orghttps://www.resonanceglobal.comhttps://www.zenysis.comhttps://www.mastercard.us/en-us.htmlhttps://www.hunuvat.comhttps://newsdocmedia.com#globalhealth #digitalinnovation #healthcaredata #newmedicines #humancentereddesign #designforhealth #inclusiveinnovationchallenge

The psychedelics industry is booming. Everyone wants a piece of it — between the startup companies, the regulatory bodies, the university medical schools, and ultimately, the people in need of these products and services. As Chief Medical Officer at MINDCURE, Dr. Joel Raskin provides deep insight into the interactions between these institutions as well as his robust knowledge of the scientific process: Intro (0:00 – 2:10) Exciting Times (2:11 – 3:50) Two Sides of the Same Coin (3:51 – 5:12) First Encounters with Psychedelic Treatments (5:13 – 7:16) A Rigorous Process (7:17 – 10:37) Integrating Psychedelics' History into Western Science (10:38 – 13:51) Excitement About the Unknown (13:52 – 16:34) What It's Like in Startup-Land (16:35 – 19:27) Getting Past Your Own Interests To Help People (19:28 – 22:31) A New Chapter (22:32 – 25:08) End (25:09 – 25:52)

New data shows that the federal P-M-P-R-B regulations are already stopping what Canadians want: access to new medicines as soon as possible. What needs to be done to make medicines and vaccines accessible? To help us with the discussion is Dr. Jason Field. Jason is the CEO and president of Life Sciences Ontario, a member-driven organization dedicated to advancing the province's vibrant life sciences sector.

The Life and Times of Richard Evans Schultes – Schultes was a scholarship student at Harvard College when entered as a Freshman in 1933. An undergraduate term paper on peyote resulted in an opportunity to partake in a traditional ceremony with the Kiowa in Oklahoma, which then led to research in southern Mexico where he produced the first detailed, scientific account of the so-called “magic mushrooms.” Post-graduate research led him to the Colombian Amazon where he produced the first detailed scientific account of ayahuasca and other Plants of the Gods. In 1967, he organized a conference in San Francisco with Albert Hoffman where the conclusion was that the Plants of the Gods would reshape the treatment of certain emotional and psychiatric disorders at some point in the future, a prediction, which has recently come to full fruition. Sources: Kreig, Margaret. Green Medicine: the Search for Plants That Heal. Bantam Books, 1966. Mann, John. Murder, Magic, and Medicine. Oxford University Press, 2000. Plotkin, Mark J. Ph. D. Tales of a Shaman's Apprentice: an Ethnobotanist Searches for New Medicines in the Amazon Rain Forest. Viking, 1993. Prance, Ghillean T., et al. Ethnopharmacologic Search for Psychoactive Drugs. Synergetic Press, in Association with Heffter Research Institute, 2018.   Stewart, Amy, et al. Wicked Plants: the Weed That Killed Lincoln's Mother & Other Botanical Atrocities. Algonquin Books of Chapel Hill, 2009.

Curare – Once known as the “flying death of the Amazon,” curare is a mixture of rainforest plants that indigenous peoples smear on the tips of their arrows or blowdarts to give them a deadly effectiveness. In the hands of western physicians, however, curare has been converted into a life-sustaining medication, a muscle relaxant in abdominal surgery.  Sources: Balick, Michael J., and Paul Alan Cox. Plants, People, and Culture the Science of Ethnobotany. CRC Press, 2020.   Marks, Geoffrey, and William K. Beatty. The Medical Garden: Illustrated. Charles Scribner's Sons, 1971.  Plotkin, Mark J. Amazon: What Everyone Needs to Know®. Oxford University Press, 2020.  Plotkin, Mark J. Tales of a Shaman's Apprentice: an Ethnobotanist Searches for New Medicines in the Amazon Rain Forest. Viking, 1993.  Prance, Ghillean T., et al. Ethnopharmacologic Search for Psychoactive Drugs. Synergetic Press, in Association with Heffter Research Institute, 2018.  Schultes, Richard Evans., and Albert Hofmann. Plants of the Gods. Vandermarck, 1979. 

Hallucinogenic snuffs – though most hallucinogens like magic mushrooms or ayahuasca are taken orally, the indigenous peoples of Amazonia have created two different and highly potent snuffs from Amazonian trees which they consume for a variety of healing and divinatory purposes. As with ayahuasca, the author draws on his personal insights and experiences with these plants and these peoples to describe the biocultural importance of these snuffs.  Sources: Chagnon, Napoleon A. The Fierce People. Holt, Rinehart & Winston, 1968.  Plotkin, Mark J. Amazon: What Everyone Needs to Know®. Oxford University Press, 2020.  Plotkin, Mark J. Tales of a Shaman's Apprentice: an Ethnobotanist Searches for New Medicines in the Amazon Rain Forest. Viking, 1993. Prance, Ghillean T., et al. Ethnopharmacologic Search for Psychoactive Drugs. Synergetic Press, in Association with Heffter Research Institute, 2018.  Schultes, Richard Evans, and Robert F. Raffauf. Vine of the Soul: Medicine Men, Their Plants and Rituals in the Colombian Amazonia. Synergetic Press, 2004.  Schultes, Richard Evans., and Albert Hofmann. Plants of the Gods. Vandermarck, 1979.   

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Seth Lederman, co-founder, CEO and chairman of Tonix Pharmaceuticals. Seth and Mike explored the two programs Tonix are currently developing in pain and psychiatry, areas where many larger companies have turned their back due to subjective endpoints. Tonix believes they have developed invaluable expertise to counter these challenges and Seth explains that the difficulty of the endpoints, will be compensated by the importance of bringing new medicines to market that will be significant to the pharmacopeia. Tonix is also working on a vaccine candidate for COVID-19 that is one of only a handful which is a live replicating virus vector platform. Seth discussed what the vaccine landscape might look like once COVID vaccines come to market and the adoption challenges we may face as a society. Seth also touched on the trend currently in the industry of biotechnology companies choosing to commercialise their products, how Tonix intend to do just this and discusses how technology has eroded big pharma's advantage in this area. See acast.com/privacy for privacy and opt-out information.

Guest John Adams, one of the authors of the paper, cofounder and CEO of Canadian PKU and Allied Disorders Inc. and volunteer board chair of Best Medicines Coalition

Today I interviewed my mom who is an expert in this topic

This episode talks about research about COVID-19, angiotensin converting enzyme (ACE), and targeted therapies, and our feature is an interview with CU-Boulder scientists Anushree Chatterjee and Prashant Nagpal. This husband and wife science team explains why there may be a downside to adapting old medications to fight Covid-19.  They’ll also explain their anguish about why creating new “drugs” to fight Covid-19 cannot happen as fast as they or anyone would like.  They have founded the Antimicrobial REgeneration Consortium, with the goal of speeding up the creation and availability of antimicrobial medicines.  They are also developing a way to give people a tiny dose of nanoparticles--basically incredibly tiny microchips, preprogrammed to specifically target a disease such as Covid-19  (see our earlier discussions with them). Host: Beth Bennett, Angele Sjong, Shelley Schlender, Joel Parker Producer: Joel Parker, Beth Bennett Engineer: Maeve Conran Executive Producer: Joel Parker Listen to the show:

Patrick interviews Dr Jeff Barrett from Genomics PLC about how genetic data can be used for drug discovery and the future of precision medicine. In this episode, Dr Barrett talks about going beyond genes to understand how they affect particular genetic risks and conditions. They also discuss the closeness of the genetics community and the sharing spirit when it comes to research.

Patrick interviews Dr Jeff Barrett from Genomics PLC about how genetic data can be used for drug discovery and the future of precision medicine. In this episode, Dr Barrett talks about going beyond genes to understand how they affect particular genetic risks and conditions. They also discuss the closeness of the genetics community and the sharing spirit when it comes to research.

In This episode Pranoti sits down with Kameron Kilchrist, a Postdoctoral Research Fellow at Janssen Research & Development at the time of recording, to take a deeper dive into Kameron‘s research journey. This vintage episode of the Under the Microscope podcast was originally released on 29.01.2020.

This episode's guest is Kameron Kilchrist, who was a Postdoctoral Research Fellow at Janssen Research & Development at the time of recording. This vintage episode of the Under the Microscope podcast was originally released on 26.01.2020.

How do we develop new medicines to treat nasty diseases? It all starts by discovering a novel target molecule in the lab. Fast forward 12 years and an average expenditure of 1.5 billion dollars we hopefully get the thumbs up from health authority bodies to license the medicine for public use. So we skipped a lot of important steps there. The journey for developing new medicines is extremely lengthy and complicated. Fortunately, you can listen to this podcast and know all the important stuff in 20 minutes! Statisticians are involved in all aspects of drug development. Having knowledge of the process from start to finish is important, as it will help you understand why statistics is an essential and relied upon toolkit in this industry. - Quick overview of the drug development process - Where and why statisticians add value in the process - Key stakeholder interactions - who do statisticians collaborate with?

Director of Multichannel Content for Pulmonary Fibrosis News, Michael Morale, discusses how AstraZeneca turned to artificial intelligence to speed discovery of new medicines for IPF. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit https://pulmonaryfibrosisnews.com/

This week, Sen and Louise discuss the infographic published in the most recent edition of GOLD. This displays a breakdown of all new drug approvals by the EMA and FDA in 2018, highlighting examples of unique therapies now available for patients.

Dr. David REYNOLDS, Chief Scientific Officer, Alzheimer’s Research UK, Cambridge, UK speaks on "Translating dementia research towards new medicines". This Movies has been recorded at ICGEB Trieste.

Dr Lichter presents, at a press conference at ASCO 2015, a new intelligence network called CancerLinQ. CancerLinQ is assembling vast amounts of usable, searchable, real-world cancer information into a powerful database. This data supports efforts to improve quality of care and hasten development of new medicines.

Fireflies light up the summertime night, but the glowing molecules inside them are also used by scientists to make new drugs.

Sep. 5, 2015. At the 2015 Library of Congress National Book Festival in Washington, D.C., John Hemming discusses "Naturalists in Paradise: Wallace, Bates and Spruce in the Amazon." Afterwards, Mark Plotkin and David Good recount their travels and adventures among the peoples of the South American rainforest. Speaker Biography: Best-selling author John Hemming is a distinguished historian and explorer of South America with a lifelong affection for the Amazon. He has visited approximately 45 indigenous peoples, been on a first exploration of a major tributary, led one of the largest scientific research projects in the region and visited many parts of the region's great river system. Ten of Hemming's books are related to the Amazon, including a three-volume history of Brazilian Indians and the acclaimed "Tree of Rivers: The Story of the Amazon." His latest book, "Naturalists in Paradise: Wallace, Bates and Spruce in the Amazon," describes the achievements of three outstanding scientists in the mid-19th century. Hemming served as director of the Royal Geographic Society in London for 21 years and is also well known for his best-selling book "The Conquest of the Incas." Speaker Biography: Mark Plotkin is an ethnobotanist and expert on rainforest ecosystems. In 1995 he co-founded the Amazon Conservation Team, which partners with local indigenous peoples to protect the rainforest. Plotkin has received various awards for his work including the San Diego Zoo Gold Medal for conservation and the Roy Chapman Andrews Distinguished Explorer Award. His articles have been featured in Harvard magazine, Forbes and The Huffington Post. Plotkin's books include "The Killers Within: The Deadly Rise of Drug-Resistant Bacteria" (Back Bay) and "Tales of a Shaman's Apprentice: An Ethnobotanist Searches for New Medicines in the Amazon Rain Forest." Speaker Biography: David Good is a graduate of East Stroudsburg University in Pennsylvania with degrees in biology; he is a member of a remote indigenous tribe known as the Yanomami. His village, known as Irokai-teri, is situated deep in the Amazon rain forest of southeast Venezuela. His father, Dr. Kenneth Good, a prominent American anthropologist, met David Good's mother, Yarima, while living and working with the Yanomamo tribe. Good reunited with his mother in 2011, after 20 years of separation and no contact. In 2013 he returned to Venezuela to rekindle his relationship with his mother and indigenous family. Good was inspired by his work and experience among indigenous peoples to create the education based nonprofit foundation The Good Project. For transcript, captions, and more information, visit http://www.loc.gov/today/cyberlc/feature_wdesc.php?rec=6985

Listen to hear more about all the latest new medicines and the experimentation Scientists have recently done!

The tropical waters of the Pacific Ocean are one of the richest sources of biodiversity on Earth. It not only teems with life, but also with extraordinary chemical compounds not found on land. Eric Schmidt, Ph.D., professor of medicinal chemistry at the University of Utah, searches marine organisms for novel compounds that could be transformed into therapeutics, such as medicines to combat pain or cancer. He discusses why there is chemical diversity underwater, what he has found, and what marine life is teaching about synthesizing compounds with new therapeutic potential.

Chas Bountra, a popular speaker at the recent Meeting Minds: Alumni Weekend in Asia, will explain how Oxford is creating a new ecosystem for drug discovery.

Chas Bountra, a popular speaker at the recent Meeting Minds: Alumni Weekend in Asia, will explain how Oxford is creating a new ecosystem for drug discovery.

How does medicine work? How are new drugs made? What role does the pharmaceutical industry play? Professors Stefan Knapp and Chas Bountra joined Science Oxford Live in spring 2013 for an evening of Scientists on the sofa, to take your questions. Have you really got a model for how this ought to work? I wanted to comment about the publication of negative findings. Have you been involved? What is your view on this? How quickly do you think it will happen? You spoke about the research institutes closing down; are they closing down in the UK and relocating, or are they just closing? Is there something to be said for slowing, or stopping, research for diseases of old age, for example Alzheimer's, and instead concentrating on scanning the genome of very young human beings to see what they might get in their future years? In regards to what you were saying about people reacting differently to a drug; that must mean that for a long time doctors have been prescribing things that don't work, and nobody's admitted it? Is that right? Because we are all so very different?

How does medicine work? How are new drugs made? What role does the pharmaceutical industry play? Professors Stefan Knapp and Chas Bountra work in the field of drug discovery. They joined Science Oxford talks in spring 2013. Society is increasingly desperate for novel medicine. Most drugs used today were developed more than 40 years ago. With our ageing population, the incidence of diseases such as dementia, cardiovascular disease, and cancer will increase exponentially over the coming years.

How does medicine work? How are new drugs made? What role does the pharmaceutical industry play? Professors Stefan Knapp and Chas Bountra work in the field of drug discovery. They joined Science Oxford talks in spring 2013. Over the past 30 to 40 years there have been drastic changes in the way new medicines are developed. Before the 1970s drug development was based on phenotypic assays and 'accidental findings', with an approval process that would often take two to three years to complete. Scientists now have a better understanding of the mechanisms leading to disease development, allowing the selection of 'targets' - regulators which are dysfunctional in the disease - allowing scientists to develop new drugs, which inhibit these cellular targets.

Many modern medicines are derived from plants.

Modern medicine uses many compounds which are isolated from plants. For example, vinblastine, which is used to treat many types of cancer, is isolated from the leaves of the Madagascar periwinkle. Sarah O'Connor will talk about her work in understanding the process by which the plant makes this substance. Not only will this lead to cheaper vinblastine but also to the production of slightly modified versions of vinblastine which may have improved medicinal properties.

In this edition, UCTV’s premier magazine program features UC Berkeley students focused on alleviating poverty as part of UCB’s Global Poverty and Practice program, the fastest-growing minor on campus. From the UC Davis Medical Center, a look at how doctors at the Pain Management Clinic are teaching patients to cope with chronic pain without becoming addicted to drugs. Then, another angle on climate change – what UC scientists are discovering about its impact on human health. And finally, from the Scripps Institution of Oceanography at UC San Diego, searching for exotic medicines in the tropics of Panama. Series: "State of Minds" [Public Affairs] [Health and Medicine] [Humanities] [Education] [Show ID: 17089]

In this edition, UCTV’s premier magazine program features UC Berkeley students focused on alleviating poverty as part of UCB’s Global Poverty and Practice program, the fastest-growing minor on campus. From the UC Davis Medical Center, a look at how doctors at the Pain Management Clinic are teaching patients to cope with chronic pain without becoming addicted to drugs. Then, another angle on climate change – what UC scientists are discovering about its impact on human health. And finally, from the Scripps Institution of Oceanography at UC San Diego, searching for exotic medicines in the tropics of Panama. Series: "State of Minds" [Public Affairs] [Health and Medicine] [Humanities] [Education] [Show ID: 17089]

There are several explanations for why new medicine appear to work better than older medicines...